Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs EPR Properties — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while EPR Properties trades at $60.14 (market cap $4.56B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and EPR Properties pays a 6.25% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | EPR | |
|---|---|---|
Market Cap | $8.04B | $4.56B |
Sector | Health | Real Estate |
52-Week High | $339.75 | $60.81 |
52-Week Low | $241.71 | $48.71 |
Enterprise Value | $7.85B | $7.62B |
Dividend Yield | — | 6.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
EPR Properties trades at $59.81, up 0.32% today, with a bullish technical signal from moving averages and strong fundamentals including a 39.93% net income margin and consistent dividend payments. Recent earnings show mixed results with a Q1 2026 miss but previous quarters beating expectations. The company maintains robust cash flow from operations of $421 million in 2025 and high portfolio occupancy.
Outlook remains positive with a consensus price target of $63.00, though risks include reliance on experiential real estate and market sensitivity. The stock offers a compelling blend of income and growth, supported by analyst buy ratings and recent acquisitions like the Six Flags park deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
